First-line treatment with targeted therapies plus chemotherapy offered overall response benefits in BRAF V600E-mutant ...

The prescribing information for two respiratory syncytial virus (RSV) vaccines will now include a warning for the increased ...

Tempus AI is projected to achieve 30% YoY top line growth in Q4 2024 as presented in its preliminary results. Click here to ...

A small, but positive, randomized double-blind trial of baricitinib for PMR is the first in patients with the condition to ...

Jefferies analyst Peter Welford maintained a Hold rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of £14.50. The ...

GlaxoSmithKline (GSK – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Graham Parry from ...

Ana Botin, executive chair of Spanish bank Santander has denied reports that the company is considering leaving the British ...

The MRHA, which overseas the safety of medicines, vaccines and healthcare devices, was accused of not acting fast enough when ...

We recently published a list of 12 Undervalued Defensive Stocks for 2025. In this article, we are going to take a look at ...

Arriving on Slough High Street on a grey weekday morning, I have barely had time to take out my notebook when I am accosted ...

MHRA’s independence also questioned during Commons debate, with regulator accused of being too close to companies it ...